Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 10 11 12 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Numaferm–SEVERAL: investment, 201705 seed financing round €7-digit from HTGF + Detlev Riesner + Jürgen Schumacher + EIF 2017-05-11
BC Platforms–Debiopharm: investment, 201705 financing round Series B totalling $10m co-led by Debiopharm Innovation Fund + Tesi 2017-05-09
BC Platforms–SEVERAL: investment, 201705 financing round Series B $10m co-led by Debiopharm Innovation Fund + Tesi 2017-05-09
BC Platforms–Tesi (FI): investment, 201705 financing round Series B totalling $10m co-led by Debiopharm Innovation Fund + Tesi 2017-05-09
Grzybowski Scientific Inventions–Merck (DE): investment, 201705 acquisition of GSI by Merck 2017-05-09
Aadi Bioscience–Helsinn: investment, 201705 financing round Series A totalling $23m incl $2m from co-investor Helsinn Investment Fund 2017-05-08
Aadi Bioscience–SEVERAL: investment, 201705 financing round Series A $23m led by Hermed Capital with Celgene + Vivo Capital + Helsinn et al 2017-05-08
CRISPR Therapeutics–MIT: lipid nanoparticle technolgy, 201705– excl license for family of LNP technologies for in vivo gene editing applications 2017-05-08
Genetrix (ES)–SEVERAL: investment, 201705– capital increase up to €10m w rights offering + private placement Sygnis AG 2017-05-08
Innova Biosciences–Genetrix (ES): investment, 201705–201707 acquisition €8m cash + 2m Sygnis shares plus up to 1.5m shares by Sygnis AG 2017-05-08
Luxendo–Bruker Corp: investment, 201705 acquisition €na of Luxendo GmbH by Bruker 2017-05-08
Medigene–SEVERAL: investment, 201705 private placement €20.7m 1.965m new shares at €10.55/share to institutional investors 2017-05-04
MVZ für Laboratoriumsmedizin am Hygiene-Institut–Eurofins: investment, 201705– acquisition of Hygel by Eurofins ANNOUNCED 2017-05-04
Vivet Therapeutics–Columbus Venture Partners: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor CVP 2017-05-04
Vivet Therapeutics–Kurma: investment, 201705 financing round Series A totalling €37.5m incl co-investor Kurma Partners 2017-05-04
Vivet Therapeutics–Novartis: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor Novartis Venture Fund 2017-05-04
Vivet Therapeutics–Odlander Fredrikson: investment, 201705 financing round Series A totalling €37.5m incl co-investor HealthCap 2017-05-04
Vivet Therapeutics–Roche: investment, 201705 financing round Series A totalling €37.5m incl co-investor Roche Venture Fund 2017-05-04
Vivet Therapeutics–SEVERAL: investment, 201705 financing round Series A €37.5m led by Novartis Venture Fund + Columbus Venture Partners 2017-05-04
Vivet Therapeutics–Ysios Capital: investment, 201705 financing round Series A totalling €37.5m incl co-investor Ysios Capital 2017-05-04
AstraZeneca–Pieris: anticalin technology, 201705– collab developm + commerc $57.5m upfront + near-term inhaled respiratory drugs incl PRS-060 2017-05-03
PharmaCell–Lonza: investment, 201704 acquisition of PharmaCell BV by Lonza 2017-05-03
ImCheck Therapeutics–Boehringer: investment, 201705 financing round Series A totalling €20m incl co-lead investor BIVF 2017-05-02
ImCheck Therapeutics–Gimv: investment, 201705 financing round Series A totalling €20m incl co-investor Gimv 2017-05-02
ImCheck Therapeutics–Idinvest Partners: investment, 201705 financing round Series A totalling €20m incl co-lead investor Idinvest 2017-05-02
ImCheck Therapeutics–Kurma: investment, 201705 financing round Series A totalling €20m incl co-lead investor Kurma Partners 2017-05-02
ImCheck Therapeutics–Life Sciences Partners: investment, 201705 financing round Series A totalling €20m incl co-investor LSP 2017-05-02
ImCheck Therapeutics–SEVERAL: investment, 201705 financing round Series A €20m from BIVF + Kurma Partners + Idinvest + Gimv + LSP 2017-05-02
Magenta Therapeutics–Novartis: cell therapy product, 201705– license to MGTA-456 (HSC835) to expand cord blood stem cells for transplants 2017-05-02
Magenta Therapeutics–SEVERAL: investment, 201705 financing round Series B $50m led by GV + incl Atlas Venture + Third Rock Ventures et al 2017-05-02
Noxxon–SEVERAL: investment, 201705 private placement €1m capital increase incl €250k fron YA II PN Ltd 2017-05-02
Noxxon–Yorkville: credit, 201705–201811 convertible bonds up to €10m to YA II PN Ltd TERMINATED 11/18 2017-05-02
Caladrius–Hitachi: investment, 201705 acquisition of PCT LLC by Hitachi Chemical 2017-05-01
Aduro Biotech–Univ Bonn: cancer immunotherapy, 201704– license for STING agonists via Provendis to Aduro Biotech 2017-04-27
Arsanis–SEVERAL: investment, 201704 financing round Series D $45.5m led by Gates Foundation + incl GV + Alexandria Venture Investments et al 2017-04-26
Epigenomics–SEVERAL: investment, 201704–201707 public cash takeover offer €7.52/share FAILED valuing ECX at €171m incl net cash by CFUC + Biochain 2017-04-26
Microsaic–SCPA GmbH: chromatography software, 201704– collab integration of 4000 MiD MS system with PrepCon 5 preparative data + control s/w 2017-04-26
EMBL–Enamine: chemical compound library, 201704– collab library synthesis + medical chemistry + biological services for cancer drug research 2017-04-25
Forge Therapeutics–Evotec: investment, 201704 financing round Series A totalling $15m incl co-investor Evotec AG 2017-04-25
Forge Therapeutics–SEVERAL: investment, 201704 financing round Series A $15m led by MagnaSci Ventures + incl Evotec + Alexandria Venture et al 2017-04-25
KSK Diagnostics–Hamburg (govt): investment, 201704 financing round with HTGF + Innovationsstarter Fonds Hamburg 2017-04-24
KSK Diagnostics–High-Tech Gründerfonds: investment, 201704 financing round with HTGF + Innovationsstarter Fonds Hamburg 2017-04-24
KSK Diagnostics–SEVERAL: investment, 201704 financing round with HTGF + Innovationsstarter Fonds Hamburg 2017-04-24
Merck (DE)–Fresenius: investment, 201704–201709 acquisition €156m upfront + €500m milestones + royalties of Merck biosimilars business in Vaud CH 2017-04-24
Wilex–SEVERAL: investment, 201704– capital increase €4.99m with rights issue to existing shareholders incl dievini Hopp 2017-04-24
BioInvent–Merck (DE): bioreactors, 201704 supply full line of Mobius single-use bioreators to BioInvent upstream facility in Lund 2017-04-20
Seracell Pharma–Vita 34: investment, 201704– conditional 100% acquisition of up to €14m ANNOUNCED 2017-04-20
Gustavus Adolphus College–Agilent: grant, 201704– Thought Leader Award to Dwight Stoll to for 2D-LC research 2017-04-19
Hookipa–Instinctif Partners: public relations, 201704 service existent by Instinctif Partners 2017-04-19
Thermo Fisher–Univ Basel: DNA sequencing, 201704– collab Univ Hospital joins NGS Companion Dx Center of Excellence Program 2017-04-18
Bayer–Ten Bridge Communications: public relations, 201704 service existent CRISR Tx/Bayer jv Casebia by Ten Bridge 2017-04-17
CRISPR Therapeutics–StrideBio: AAV vectors, 201704– collab developm + license option usingStrideBio’s vectors for in vivo CRISPR/Cas9-based therapies 2017-04-17
MOCON–AMETEK: investment, 201704– acquisition of MOCON Inc for aggregate enterprise value of $182m 2017-04-17
Polyphor–SEVERAL: investment, 201704 private financing round CHF40m with CHF10m upfront + CHF30m at positive ph2 study end in 2017H2 2017-04-12
Adhesys Medical–Grünenthal: investment, 201704 acquisition of Adhesys by Grünenthal 2017-04-07
Adhesys Medical–GSK Stockmann: legal services, 201704 supply legal advisor for sale of Adhesys Medical to Grünenthal 2017-04-07
Biotest–Ashurst: legal services, 201704 supply service legal advisor with regard to sale of Biotest AG to Ceat Group (CN) 2017-04-07
Asceneuron–Instinctif Partners: public relations, 201704 service existent by Instinctif Partners 2017-04-06
Berlin Institute of Health–Labfolder: electronic lab notebook, 201704– supply license Labfolder s/w to BIH (Charité + MDC) 2017-04-06
Labfolder–MC Services: public relations, 201704 service existent by MC Services AG 2017-04-06
Novartis–Lubris: rh lubricin, 201704– license €na exercise of option for ECF843 for ophthalmic indications ww excl Europe 2017-04-06
Biosyntia–FGen: biological vitamin production, 201704– collob developm of microbial strains for production of specific B vitamins 2017-04-05
MTIP MedTech Innovation Partners–SEVERAL: investment, 201704 final closing w addit CHF30m bringing total fund size of 1st MTIP Fund to CHF60m 2017-04-04
Topas Therapeutics–MC Services: public relations, 201704 service existent by MC Services AG 2017-04-04
MKS Instruments–Sartorius: investment, 201704 acquisition $72.5m of MKS Instruments AB (Umetrics) by Sartorius Stedim Biotech 2017-04-03
Bentekk–Dräger: investment, 201704 acquisition of majority stake by Dräger 2017-04-01
Yumda–Chemie.DE: investment, 201704 acquisition of Yumda GmbH by Chemie.DE Information Service GmbH 2017-04-01
Eisai–Calypso Biotech: therapeutic antibody, 201703– ww license + collab for MMP-9 MAb CALY-001 with EA Pharma Co Ltd 2017-03-31
Innovative Medicines Initiative–Qiagen: cancer biomarker, 201703– collab Qiagen joins CANCER-ID project 2017-03-30
Novartis–Oxford BioMedica: lentiviral vector technology, 201703 supply existent OBM sole producer of lentiviral vector expressing CTL019 2017-03-30
Symetis–Boston Scientific: investment, 201703– acquisition $435m in cash ANNOUNCED 2017-03-30
Biotest–Creat (CN): investment, 201703–201801 public cash tender offer €1.3b incl net debt for all shares w €28.5/ordinary + €19m/preference share 2017-03-29
Versantis–SEVERAL: investment, 201703 financing round Series A CHF4.4m led by Redalpine Venture Partners 2017-03-29
Bayer–Icagen: drug discovery assays, 201703– collab developm of XRpro Assays for early discovery programs in area of transporter targets 2017-03-28
Menarini–Selvita: kinase inhibitor, 201703– license ww to dual PIM/FLT3 kinase inhibitor SEL24 to Berlin-Chemie 2017-03-28
Ono Pharmaceutical–Numab: antibody cancer drug, 201703– research + option agreem up to CHF258m + royalties for multi-specific antibody 2017-03-28
Institut Pasteur–Bruker Corp: NMR spectrometer, 201703 supply existent early customer for AVANCE NEO 800 MHz system 2017-03-27
PureTech Health–Novartis: investment, 201703 equity position in new resTORbio subsidary for Novartis as part of mTORC1 inhibitor license deal 2017-03-24
PureTech Health–Novartis: mTORC1 inhibitors, 201703– license excl to 2 clin stage programs to be developed by new resTORbio subsidary 2017-03-24
Numares–Univ Oxford: NMR-based IVD tests, 201703– collab developm of multiple sclerosis test using Axinon IVD system + MGS technology 2017-03-23
BASF–MIT: CRISPR technology, 201703– license ww for agricultural + industrial microbiology applications from Broad Institute 2017-03-22
Symetis–SEVERAL: investment, 201703 IPO at Euronext NOT REALISED because of acquistion offer by Boston Scientific 2017-03-17
Medac–Cevec: rec protein production technology, 201703– license to CAP GT technology for oncology products 2017-03-16
Provecs–Cevec: rec protein production technology, 201703– license non-excl extension to CAP GT technology for cancer immunotherapy 2017-03-16
CRISPR Therapeutics–MaxCyte: gene transfer technology, 201703– license non-excl to CRISPR Tx + Caseio for using Flow Electroporation technology 2017-03-14
NeoGenomics–AstraZeneca: cancer research tests, 201703– collab using automated Definiens biomarker solutions for IHC services of NeoGenomics 2017-03-13
ILC Micro-Chem–SGS: investment, 201703 acquisition of ILC by SGS 2017-03-09
Breath Therapeutics–Gimv: investment, 201703 financing round Series A totalling €43.5m incl co-led by Gimv + Sofinnova Partners 2017-03-08
Breath Therapeutics–MC Services: public relations, 201703 service existent by MC Services AG 2017-03-08
Breath Therapeutics–SEVERAL: investment, 201703 financing round Series A €43.5m co-led by Gimv + Sofinnova Partners 2017-03-08
Breath Therapeutics–Sofinnova: investment, 201703 financing round Series A totalling €43.5m incl co-led by Gimv + Sofinnova Partners 2017-03-08
Fresenius–Wacker: rec protein production, 201703 collab use of Wacker Biotech’s FOLDTEC technology to produce Fabs for Fresenius 2017-03-08
Illumina–Endress+Hauser: automated liquid handling, 201703– collab developm + marketing of AJ CyBio FeliX system with Infinium XT BeadChip 2017-03-08
InGeneron–Sanford Health: investment, 201703– tranched investment Series D $20m from Sanford Health 2017-03-06
Alcami–Bruker Corp: X-ray technology, 201703 supply of D8 Discover HTS XRD system to Alcami site in Weert NL 2017-03-03
Essen BioScience–Sartorius: investment, 201703–201704 acquisition $320m in cash of Essen BioScience from SFW Capital Partners 2017-03-03
Neurovance–Novartis: investment, –201703 existent investment of NVF when acquisition of Neurovance by Otsuka announced 2017-03-03
Neurovance–Otsuka: investment, 201703– acquisition $100m upfront + $150m milestones of Neurovance by Otsuka America Inc 2017-03-03
CRISPR Therapeutics–W2O Group: public relations, 201703 service existent by W2O Group 2017-03-02
CRISPR Therapeutics–Westwicke Partners: public relations, 201703 service existent investor relations by Westwicke Partners 2017-03-02
next pagenext page 1 2 3 ... 10 11 12 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top